{"id":19555,"date":"2023-12-19T16:37:31","date_gmt":"2023-12-19T05:37:31","guid":{"rendered":"https:\/\/mvec.mcri.edu.au\/?post_type=references&p=19555"},"modified":"2025-12-12T12:54:18","modified_gmt":"2025-12-12T01:54:18","slug":"digeorge-syndrome-and-vaccines","status":"publish","type":"references","link":"https:\/\/mvec.mcri.edu.au\/vi\/references\/digeorge-syndrome-and-vaccines\/","title":{"rendered":"DiGeorge syndrome and vaccines"},"content":{"rendered":"
<\/p>\n

L\u00fd l\u1ecbch<\/h2>\n

DiGeorge syndrome (also known as velocardiofacial syndrome or 22q11.2 deletion syndrome) is a genetic condition affecting approximately 1 in 2,000 newborns. It involves the deletion of DNA in the q11 region of the long arm of chromosome 22 during foetal development. Most cases occur as the result of a random gene mutation. However, in some instances the mutation can be inherited from a parent. <\/span>\u00a0<\/span><\/p>\n

The health implications of the deleted DNA sequence can vary between individuals. Common features include congenital heart defects, small or absent thymus, cleft or palate abnormalities, speech\/language and developmental delay, hearing and visual problems, and learning difficulties. Immunodeficiency is also commonly associated with DiGeorge syndrome. This may be related to inadequate T-cell function, decreased levels of immunoglobulin or reduced antibody function. \u00a0<\/span>\u00a0<\/span><\/p>\n

DiGeorge syndrome and <\/span>
<\/div><\/span><\/h2>\n

The decrease<\/span> in<\/span> immune function <\/span>v\u00ec<\/span> many<\/span> people with <\/span>DiGeorge <\/span>syndrome means that v<\/span>accination is particularly important<\/span> \u0110\u1ebeN <\/span>provide<\/span> protection against <\/span>vaccine-preventable diseases. <\/span>However<\/span>,<\/span> it is important to <\/span>recognise<\/span> that the immune response to vaccines may be <\/span>suboptimal <\/span>meaning<\/span> th\u00eam v\u00e0o<\/span> do<\/span>ses of vac<\/span>cines may be recommended. Conversely, some vaccines (live-attenuated vaccines) may be contraindicated due to the potential risk of vaccine-related disease.<\/span><\/span>\u00a0<\/span><\/p>\n

khuy\u1ebfn ngh\u1ecb<\/span><\/span><\/h3>\n

The following guidance outlines recommendations for specific investigations and vaccines for children diagnosed with DiGeorge syndrome. This guidance has been developed as a collaboration between MVEC, Queensland Children\u2019s Hospital<\/span>,<\/span> Royal Brisbane and Women\u2019s Hospital<\/span> and Perth Children\u2019s Hospital<\/span>.<\/span><\/span>\u00a0<\/span><\/p>\n

Immunological work-up and vaccination recommendations for children with 22q11 microdeletion (PDF) – December 2025<\/a><\/span><\/span><\/strong><\/p>\n<\/div>

<\/p>\n

T\u00e0i li\u1ec7u<\/h2>\n